Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

czyli wszystkie giełdy bardziej rozwinięte niż GPW
slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 27 paź 2020 17:06

Merck Third-Quarter Earnings, Sales Handily Beat Expectations; Slightly Hikes Guidance
FacebookTwitterLinkedInShare Licensing
MICHAEL KREY11:25 AM ET 10/27/2020
Merck (MRK) on Tuesday reported adjusted earnings of $1.74 per share on $12.6 billion in sales for the third quarter and slightly hiked its full-year guidance. In response, MRK stock edged higher.

On average, analysts polled by FactSet had predicted adjusted profit of $1.44 per share on $12.2 billion in sales for the drug giant.

Sales of its top product, blockbuster cancer drug Keytruda, rose 21% to $3.7 billion.

In the year-ago quarter, Merck posted earnings of $1.51 a share on $12.4 billion in sales. So, sales edged higher 1% while per-share earnings jumped 16%.

IBD Newsletters
Get exclusive IBD analysis and action news daily.
SIGN UP NOW!
For the year, the New York-based company guided to earnings of $5.91-$6.01 a share on sales of $47.6 billion-$48.6 billion. With its second-quarter earnings, Merck guided to earnings of $5.63-$5.78 a share on sales of $47.2 billion to $48.7 billion.

Analysts project adjusted earnings of $5.72 per share on $48 billion in sales. Those numbers would result in earnings rising 10% and sales edging higher 2%.

MRK Stock Had Dipped Below 50-Day Line
The company, with partners, is working on both Covid-19 vaccine candidates and treatment candidates. At this point, it lags other vaccine and drug therapy efforts.

In its earnings release, Merck said the Covid-19 pandemic lowered its sales by about $475 million last quarter, bringing the company's year-to-date negative impact on revenue to about $2.1 billion.

Also, the company said lower back-to-school demand hurt sales of its vaccines, especially Gardasil 9. Its third-quarter sales tumbled 10% to $1.19 billion.

Last week, the Kenilworth, N.J.-based company reported positive late-stage clinical trials for a pneumococcal vaccine candidate.

MRK stock edged up a fraction to 79 in morning trading in the stock market today. Shares fell 1.2% on Tuesday.

Shares of MRK stock this month have fallen below their 50-day and 200-day lines. MRK stock last week touched a nearly three-month low of 78.03. Last month, shares touched a nearly nine-month high of 87.80.

Currently, MRK stock has formed a flat base, with a potential buy point of 87.90.

The Covid-19 pandemic has slowed Merck and many of its rivals as patients have delayed procedures and have had less access to health care providers.

https://www.investors.com/news/technolo ... -guidance/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

REKLAMA


slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 20 lis 2020 14:55

#Merck hiked its dividend by 6.6 percent, marking the 10th consecutive year of dividend increases.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 02 gru 2020 17:15

Merck sprzedał udziały w Modernie

ARŻ, REUTERS opublikowano: dzisiaj, 02-12-2020, 15:37
Koncern farmaceutyczny Merck poinformował w środę, że wycofał swoją inwestycję kapitałową w Modernę, po tym, gdy skorzystał na wzroście ceny akcji producenta potencjalnej szczepionki na koronawirusa w tym roku, pisze Reuters.

Merck nie ujawnił wysokości wpływów ze sprzedaży akcji Moderny, w które zainwestował w 2015 roku 50 mln USD. Stwierdził jedynie, że dzięki tej transakcji spodziewa się niewielkiego zysku w czwartym kwartale roku.

https://www.pb.pl/merck-sprzedal-udzial ... ie-1102115
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 03 mar 2021 10:50

Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official

Merck & Co Inc will help make rival Johnson & Johnson (NYSE:JNJ)'s single-shot COVID-19 vaccine in a partnership set to be announced on Tuesday by U.S. President Joe Biden, White House press secretary Jen Psaki said.

J&J's vaccine production has been slower than promised, and the Biden administration pushed the deal to try to improve output.

"As soon as we learned about the fact that Johnson and Johnson was behind in the manufacturing steps and efforts, we took steps to ensure we can expedite that and partner them with one of the world's biggest manufacturers," Psaki told a White House briefing.

Psaki said the U.S. government will invoke the Defense Production Act in order to equip Merck's plants to be able to produce the J&J vaccine.

She said Biden should provide more detail later on Tuesday. He is scheduled to speak on COVID-19 at 4:15 p.m. (2115 GMT)

More doses sooner could speed the U.S. vaccination effort considerably, because as a one-dose vaccine it is possible to inoculate twice as many people with the same number of shots. The other two U.S.-approved vaccines - from Pfizer Inc (NYSE:PFE) and BioNTech and Moderna (NASDAQ:MRNA) Inc - require two doses.

Under its contract, J&J was supposed to deliver 12 million doses by the end of February, but had less than 4 million ready to ship when the vaccine was authorized on Saturday.

It expects to be able to deliver another 16 million doses by the end of the month - still well short of its previous commitments - but will not ship any next week. The company has said it will be able to provide the full 100 million doses it has agreed to supply by its original midyear deadline.

The next shipments are waiting on regulatory approval of new manufacturing operations run by its partner, contract drugmaker Catalent (NYSE:CTLT) Inc, J&J Chief Scientific Officer Paul Stoffels said in an interview on Monday.

J&J did not immediately respond to a request for comment on the Merck arrangement.

Merck's collaboration with J&J comes after Merck scrapped development of its own COVID-19 vaccine candidates in January, Merck last month said it was working on a deal to open up its manufacturing capacity to other vaccine makers.

The partnership is the latest example of large drugmakers working together to help produce COVID-19 vaccines to meet the global demand.

Swiss drugmaker Novartis signed an agreement in January to fill vials for Pfizer and BioNTech's shot, while French drugmaker Sanofi (NASDAQ:SNY) SA will help fill and pack millions of doses of Pfizer's vaccine starting in July.

Merck will dedicate two U.S. facilities to J&J's vaccine, according to a report in the Washington Post, which first reported the news of the arrangement on Tuesday. (https://wapo.st/304E8ZQ)

"Merck remains steadfast in our commitment to contribute to the global response to the pandemic," the company said.

Merck to help make Johnson & Johnson's COVID-19 vaccine: White House official

https://www.investing.com/news/stock-ma ... al-2434815
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 20 mar 2021 15:47

Dywidendy

Undervalued Dividend Growth Stock of the Week: Merck & Co. (MRK)

https://dailytradealert.com/2021/03/21/ ... ck-co-mrk/

Obrazek

Time to Buy this DIRT-CHEAP Stock! One of the Best Deals for Dividend Growth Investors
https://www.youtube.com/watch?v=i_XHgZkqWsQ
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 01 maja 2021 18:44

Pozytywne oceny z rynku
Merck. Powrót pacjentów napędzi wyniki.

Choć w ubiegłym roku producent leków notowany na NYSE poprawił wyniki finansowe, to zarząd nie ukrywa, że pandemia odbiła się negatywnie na działalności spółki. Grupa odnotowała spadek przychodów w IV kwartale 2020 r. o ponad 400 mln USD. Inwestorzy mogli być też zawiedzeni decyzją o zawieszeniu prac nad lekiem przeciwko koronawirusowi. Zrezygnowano z projektu, ponieważ lekarstwo miałoby być dostępne w I połowie 2022 r.

Firma tworzy szeroką ofertę leków, jednak najważniejsze są te przeciwko nowotworom. Jak prognozują analitycy, wzrost ich sprzedaży ma być widoczny już w wynikach po I kwartale, ponieważ dzięki postępującym programom szczepień coraz więcej ludzi śmielej przychodzi do szpitali.
...
https://www.parkiet.com/Zagraniczna-Spo ... rynku.html
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 18 maja 2021 23:29

My High-Quality Dividend Stock of the Month for May 2021 is Selling at a Steep Discount Right Now - Dave van Knapp

https://www.youtube.com/watch?v=_FwqI1N2NOo
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 05 wrz 2021 13:38

Dywidendy
20.03.2021
Undervalued Dividend Growth Stock of the Week: Merck & Co. (MRK)

https://dailytradealert.com/2021/03/21/ ... ck-co-mrk/

Obrazek

Time to Buy this DIRT-CHEAP Stock! One of the Best Deals for Dividend Growth Investors
https://www.youtube.com/watch?v=i_XHgZkqWsQ
https://dailytradealert.com/2021/09/05/ ... -co-mrk-2/

https://www.youtube.com/watch?v=mxrzg0cEnoc
Ostatnio zmieniony 20 mar 2022 17:20 przez slayer74, łącznie zmieniany 2 razy.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 30 wrz 2021 17:23

Merck (MRK) rose 1.6%. The pharmaceutical company agreed to acquire Acceleron Pharma (XLRN) for $11.5 billion, or $180 a share. The deal adds to Merck's rare-disease business.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 06 paź 2021 22:52

Merck vs. Moderna: Which Vaccine Stock is a Better Investment?

Merck & Co., Inc. (MRK - Get Rating) operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. On the other hand, Moderna, Inc. (MRNA - Get Rating) develops therapeutics and vaccines based on messenger RNA to treat infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

Companies with a COVID-19 vaccine or drug in their portfolio are expected to remain in focus this year and beyond as the virus is far from gone. Moreover, the recent recommendations of healthcare organizations for booster doses are expected to generate new revenue streams for vaccine stocks. The global coronavirus vaccine market is estimated to be valued at $ 38. billion in 2021 and grow at a CAGR of 56.1% during the period 2021-2028. MRK and MRNA have been major movers in the fight to contain the coronavirus, with their breakthrough developments.

MRNA has gained 145.8% over the past six months, while MRK has returned 7.8% over this period. Also, MRNA’s 211.9% gain year-to-date compares with MRK’s 1.6% return. In terms of the past year’s performance, MRNA is the clear winner with a 373.5% gain versus MRK’s 2.9%.

But which stock is a better buy now? Let’s find out.

Latest Developments

On October 1, Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral medicine molnupiravir (MK-4482, EIDD-2801) significantly reduced the risk of hospitalization or death at a planned interim analysis of Phase 3 MOVe-OUT trial in at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19.

On September 30, MRK and Acceleron Pharma Inc. (XLRN), a biopharmaceutical company, announced that the companies have entered into a definitive agreement under which MRK, through a subsidiary, will acquire Acceleron. MRK expects this acquisition to complement and strengthen its product portfolio.

On September 24, MRNA announced its supply agreement with the government of Peru for 20 million doses of MRNA’s COVID-19 vaccine. “We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine,” said Corinne Le Goff, Pharm.D., M.B.A, Chief Commercial Officer of Moderna.

Recent Financials

MRNA’s total revenues increased 6,398.5% year-over-year to $4.35 billion in its fiscal second quarter that ended June 30. Its income from operations stood at $3.06 billion, up 2,609.8% from the same period last year. Its net income improved 2,476.1% from its year-ago value to $2.78 billion. The company’s EPS increased 2,183.9% year-over-year to $6.46.

For the second quarter that ended June, MRK’s sales increased 22% year-over-year to $11.40 billion. Sales from the pharmaceuticals segment grew 22% from its year-ago value to $9.98 billion, while its non-GAAP net income improved 28% year-over-year to $3.32 billion. The company’s non-GAAP EPS also improved 28% year-over-year to $1.31.

MRNA’s revenues grew at a CAGR of 231.7% over the past three years. Analysts expect MRNA’s revenue to increase 8,247.3% in the current quarter, 1,193.3% in the next quarter, and is expected to decline 1.6% in the next year. The company’s EPS is expected to grow 1,700% in the current quarter, 1,669.6% in the next quarter, and to decline 7.5% in the next year. Furthermore, its EPS is expected to grow at a 16.8% rate per annum over the next five years.

In comparison, MRK’s revenues grew at a CAGR of 6.9% over the past three years. Analysts expect its revenue to increase 0.3% in the current quarter, 4.6% in the next quarter, and 9.2% in the next year. The company’s EPS is expected to grow 12.4% in the current quarter, 62.2% in the next quarter, and 17.3% in the next year. Moreover, MRK’s EPS is expected to grow 12.7% per annum over the next five years.

Profitability

MRK is more profitable with a gross profit margin of 72.31%, compared to MRNA’s 59.02%. Also, MRK’s trailing-12-months revenue is 7.18 times what MRNA generates.

However, MRNA’s ROE, ROA, and ROTC of 72.43%, 24.30%, and 45.77% compare with MRK’s 20.40%, 11.47%, and 17.55%, respectively.

Valuation

In terms of forward EV/Sales, MRNA is currently trading at 6.41x, 26.4% higher than MRK, which is currently trading at 4.72x. Also, MRNA’s trailing-12-months Price/Sales ratio of 18.49 is 77.4% higher than MRK’s 4.17.

Thus, MRK is relatively affordable here.

POWR Ratings

MRK has an overall grade of B, which equates to a Buy rating in our proprietary POWR Ratings system. On the other hand, MRNA has an overall grade of C, which translates to a Neutral rating. The POWR Ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree.

MRK has a grade of B for Stability, owing to its beta of 0.42. In contrast, MRNA has a grade of F for Stability, due to a beta of 1.49.

Both the stocks have a Quality grade of B, owing to their higher-than-industry profit margins. MRK’s EBITDA margin of 39.51% is 593.3% higher than the industry average of 5.70%. On the other hand, MRNA’s EBITDA margin of 55.82% is 879.5% higher than the industry average.

Of the 212 stocks in the Medical – Pharmaceuticals industry, MRK is ranked #19. Alternatively, among the 502 stocks in the Biotech industry, MRNA is ranked #37.

Beyond what we’ve stated above, we have also rated the stocks for Sentiment, Momentum, Value, and Growth. Click here to view all of MRK’s ratings. Also, get all of MRNA’s ratings here.

The Winner

Both MRK and MRNA are expected to benefit from the continued need to fight against the virus. Relatively lower valuation and more stability make MRK a better choice here.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 28 paź 2021 18:32

Merck (MRK) soared 5% in fast trade to a 52-week high after reporting better-than-expected Q3 results. It's now extended from a 79.33 buy point of a flat base. Early Thursday, the drug giant reported adjusted Q3 EPS of $1.75 on sales of $13.15 billion. FactSet forecasts were for $1.55 EPS on $12.32 billion in sales. For the full year, Merck guided higher on profit and roughly in line on sales.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 04 lis 2021 17:45

Britain approves Merck's COVID-19 pill in world first
Stock Markets1 hour ago (Nov 04, 2021 11:37AM ET)


Britain approves Merck's COVID-19 pill in world first© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021.

(Reuters) -Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) recommended https://www.gov.uk/government/news/firs ... ed-by-mhra the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.

It will be administered as soon as possible following a positive COVID-19 test and within five days of the onset of symptoms, the regulator said, citing clinical data.

The green light is the first for an oral antiviral treatment for COVID-19 and the first for a COVID-19 drug that will be administered widely in the community. U.S. advisers will meet this month to vote on whether molnupiravir should be authorized.

Treatments to tackle the pandemic, which has killed more than 5.2 million people worldwide, have so far focused mainly on vaccines. Other options, including Gilead (NASDAQ:GILD)'s infused antiviral remdesivir and generic steroid dexamethasone, are generally only given after a patient has been hospitalised.

Merck's Molnupiravir has been closely watched since data last month showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe COVID-19 when given early in the illness.

Molnupiravir, which will be branded as Lagevrio in Britain, is designed to introduce errors into the genetic code of the coronavirus that causes COVID-19 and is taken twice a day for five days.

Professor Stephen Powis, national medical director for the National Health Service (NHS) in England, said the drug would be administered to patients at higher risk of complications as Britain heads into one of the most challenging winters ever.

A wider rollout will follow if it is clinically and cost effective in reducing hospitalisations and death, he added.

"We are now working across government and the NHS to urgently get this treatment to patients initially through a national study so we can collect more data on how antivirals work in a mostly vaccinated population," UK vaccines minister Maggie Throup told parliament.

PRESSURES

The speedy approval in Britain, which was also the first Western country to approve a COVID-19 vaccine, comes as it struggles to tame soaring infections.

Britain has about 40,000 daily cases of COVID-19, according to the latest seven-day average. That is second only to the roughly 74,000 a day in the United States, which has five times more people, and has fuelled criticism of the government's decision to abandon most pandemic-related restrictions

Data released on Wednesday night showed COVID-19 prevalence in England hit its highest level on record last month, led by a high numbers of cases in children and a surge in the south-west of the country.

Pressure is growing on the government to implement its "Plan B" aimed at protecting the NHS from unsustainable demands, involving mask mandates, vaccine passes and work-from-home orders.

Many other big economies, including Germany, France and Israel, have either retained some basic COVID-19 measures like mask mandates or reintroduced them in response to rising cases.

The UK government has said its focus remains on administering vaccine boosters and inoculating 12 to 15-year-olds.

"With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data (on molnupiravir)," MHRA chief June Raine said in a statement.

Last month, Britain agreed a deal with Merck to secure https://www.reuters.com/world/uk/britai ... 2021-10-20 480,000 courses of molnupiravir.

Professor Penny Ward, an independent pharmaceutical physician, welcomed the approval, but said the NHS needed to outline its plans for rollout and cautioned that supplies were likely to be tight given the strong global demand.

"Comments made by Mr Javid today suggest that it may be made available via a clinical trial, presumably to investigate its effectiveness in vaccinated patients with breakthrough infections, as the original study incorporated unvaccinated adults," she said.

If given to everyone becoming unwell, the nearly half a million courses would not last very long given the more than 40,000 current daily case rate, she said.

TREATMENT RACE

In a separate statement, Merck said it expected to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

The U.S. based drugmaker's shares were up 2.1% at $90.54 before the market open.

Pfizer (NYSE:PFE) and Roche are also racing to develop easy-to-administer antiviral pills for COVID-19. Pfizer last month began a large study of its oral antiviral drug for the prevention of COVID-19 in people exposed to the coronavirus.

Merck's molnupiravir is also being studied in a late-stage trial for preventing infection.

Viral sequencing done so far has shown molnupiravir is effective against all variants of the coronavirus, Merck has said, including the more-infectious Delta, which is responsible for the worldwide surge in hospitalisations and deaths recently.

While it is not yet clear when Merck will deliver doses to Britain, the company has said https://www.reuters.com/business/health ... 2021-10-17 it is committed to providing timely access to its drug globally with plans for tiered pricing aligned with a country's ability to pay.

Merck is also in talks with generic drugmakers about expanding manufacturing licences to build supply of the treatment.

Antibody cocktails like those from Regeneron (NASDAQ:REGN) and Eli Lilly (NYSE:LLY) have also been approved for non-hospitalised COVID-19 patients, but have to be given intravenously.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 27 lis 2021 09:41

Koncern farmaceutyczny Merck poinformował w piątek, że według zaktualizowanych danych pigułka przeciwko Covid-19 jest mniej skuteczna niż wcześniej zgłoszono. Molnupiravir miał być stosowany w leczeniu łagodnego lub umiarkowanego przebiegu choroby u dorosłych.

https://www.pb.pl/merck-tabletka-przeci ... no-1134584
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 10 sty 2022 21:54

Merck (MRK) outperformed in the Dow Jones today after the company announced positive data for its blockbuster cancer drug Keytruda.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!

slayer74
Kapitan
Posty: 44305
Rejestracja: 19 lip 2005 13:21
Lokalizacja: West Poland- FZ 1974

Re: Merck & Co., Inc. NYSE: MRK p. farmaceutyczny

Postautor: slayer74 » 20 mar 2022 17:22

Dywidendy
20.03.2021
Undervalued Dividend Growth Stock of the Week: Merck & Co. (MRK)

https://dailytradealert.com/2021/03/21/ ... ck-co-mrk/

Obrazek

Time to Buy this DIRT-CHEAP Stock! One of the Best Deals for Dividend Growth Investors
https://www.youtube.com/watch?v=i_XHgZkqWsQ
https://dailytradealert.com/2021/09/05/ ... -co-mrk-2/

https://www.youtube.com/watch?v=mxrzg0cEnoc
This Stock is WAY Undervalued... Now's a Great Time to Buy It
https://www.youtube.com/watch?v=hFpOy5pLW-Q

Undervalued Dividend Growth Stock of the Week: Merck (MRK)
by Jason Fieber, Mr. Free at 33 • March 20, 2022

Obrazek

https://dailytradealert.com/2022/03/20/ ... merck-mrk/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!


Wróć do „Zagranica”

REKLAMA

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 16 gości